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Plasma levels of B-type natriuretic peptide (BNP) and its
N-terminal propeptide (NT-BNP) are elevated in renal
impairment and provide a robust prognostic index. The effect
of peritoneal dialysis on plasma NT-BNP, however, is
unknown. Furthermore, no information exists regarding
levels of the N-terminal propeptide for C-type natriuretic
peptide (NT-CNP) in renal failure and the effects of peritoneal
dialysis. Accordingly, we documented venous levels of these
peptides, and adrenomedullin, across peritoneal dialysis.
We measured venous BNP, NT-BNP, NT-CNP, adrenomedullin,
blood urea nitrogen (BUN) and creatinine before, during
and after completion of overnight peritoneal dialysis in 11
patients, and identical sampling was carried out in eight
patients (controls) but between peritoneal dialysis
treatments. Peptide levels were measured using
well-validated, published methods. Baseline levels of NT-CNP
(212, 150–303 pmol/l, median and 25th and 75th percentiles)
were much higher than recorded previously in healthy
volunteers or in heart failure, and correlated with plasma
creatinine (rs¼ 0.53, Po0.05). Peritoneal dialysis had
no effect on plasma NT-CNP, nor on NT-BNP, BNP or
adrenomedullin (all elevated above normal), whereas both
BUN and creatinine levels, as expected, declined (Po0.001).
We conclude that plasma levels of NT-CNP are grossly
elevated in chronic renal failure and correlated with plasma
creatinine, but are not altered by peritoneal dialysis. Likewise,
BNP, NT-BNP and adrenomedullin are elevated but are not
altered by peritoneal dialysis. This information is needed
if levels of these hormones are to be used as prognostic
indicators or as a guide to the management of patients
with chronic renal failure.
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It is known that circulating concentrations of the bio-
active cardiac natriuretic peptides, atrial and B-type
natriuretic peptide (A-type peptide (ANP) and B-type
peptide (BNP), respectively), are elevated in patients with
impaired renal function.1,2 Most reports are that plasma
levels of these peptides relate not only to the severity of renal
dysfunction but also to indices of cardiac structure and
function such as left ventricular ejection fraction (inverse
correlation) and left ventricular diameters, left ventricular
mass index, and pulmonary artery or wedge pressure
(positive correlations).2,3 Furthermore, the CREED investi-
gators, who studied a large cohort of patients requiring
chronic dialysis, showed that plasma BNP and ANP
levels were robust predictors of total and cardiovascular
mortality.4 Accordingly, it is possible that circulating
concentrations of these peptides will provide an objective
guide for the management of such patients in regard to their
dietary habits, dialysis requirements and pharmacological
treatment.5
Interpretation of plasma cardiac natriuretic peptide
levels in patients with chronic renal failure, however, requires
an understanding of the effects of dialysis on their circulating
concentrations. Hemodialysis- and peritoneal dialysis-in-
duced effects on plasma ANP and BNP have been reported,
but it is not known whether levels of the 1–76 amino-acid
N-terminal fragment (NT-BNP) of proBNP are altered
by peritoneal dialysis. This is of potential importance
as there has been speculation that NT-BNP might provide
a better index of cardiac function or dysfunction than BNP
itself.6
The first aim in the present study, therefore, was to
document NT-BNP levels across peritoneal dialysis. The
second aim was to record plasma levels of peptides that are
likely to afford cardiovascular protection in patients with
chronic renal failure and the effects on them of peritoneal
dialysis. One is the recently discovered N-terminal fragment
(NT-C-type natriuretic peptide (CNP)) of the propeptide of
the third natriuretic peptide, CNP,7 which circulates at higher
concentrations than CNP itself. The other peptide is
adrenomedullin, which is secreted largely by the vascular
endothelium and whose levels are known to be elevated in
renal failure.8
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RESULTS
Characteristics of patients in the active and control groups
are shown in Table 1. Body weight declined across dialysis by
an average of 2.2 kg in the active group (range 0–5 kg).
Plasma levels of BNP, NT-BNP, NT-CNP and adrenomedullin
were elevated well above the normal range as determined in
healthy volunteers using the same radioimmunoassays
(Table 1). In the case of NT-CNP, the levels (212,
150–303 pmol/l, median and 25th and 75th percentiles) were
also very much higher (Po0.001) than documented
previously in 77 patients aged 7471.8 years (mean7s.e.m.)
with heart failure (32.4, 25.4–39.4 pmol/l)9 and 101 healthy
volunteers aged 66.570.8 years (18.5, 15.8–28.9 pmol/l),
again using the same assay (Figure 1). Baseline indices were
similar in the two groups of patients with chronic renal
failure except for plasma levels of NT-CNP, which were
significantly higher in the active group than in controls
(Po0.01).
A statistically significant association was noted between
baseline plasma levels of NT-CNP and creatinine (rs¼ 0.53,
Po0.05, n¼ 19, Figure 2). Patient age was not significantly
related to any of the peptide hormones but correlated
inversely with baseline levels of plasma creatinine (rs¼0.46,
Po0.05).
Plasma blood urea nitrogen (BUN) and creatinine levels
fell significantly (Po0.001) across dialysis compared to those
of controls (25 (36, 4) versus 2 (0.4, 4) mg/dl and 1.2
(2.7, 0.5) versus 0.0 (0.2, 0.4) mg/dl). By contrast,
plasma levels of BNP, NT-BNP, NT-CNP and adrenomedullin
did not change in either active or control patients (Table 2).
DISCUSSION
It is clear from previous reports that plasma levels of cardiac
natriuretic peptides are elevated in patients with chronic
renal failure.1,2 In that their levels in the plasma correlate
with haemodynamic indices and left ventricular mass and
also predict cardiovascular and total mortality,2–4 there is
every possibility that they might prove to be clinically useful
as one index of cardiac dysfunction and fluid status, and as a
guide to the complex management of patients requiring long-
term dialysis.5 Interpretation of natriuretic peptide levels,
however, requires an understanding of what factors can alter
their circulating concentrations. In this regard, it is known
that plasma levels of ANP fall substantially across both
haemodialysis and peritoneal dialysis.1,10 Compared with
ANP, plasma BNP levels exhibit no change or a lesser
percentage decline,1,11 and Wahl et al.12 reported that NT-
BNP levels were altered little by haemodialysis, falling slightly
(by 2.3%) when a high-flux membrane was used and
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Figure 1 | Plasma levels of NT-CNP in healthy volunteers
(n¼ 101), patients with heart failure (n¼ 77) and patients with
chronic renal failure (n¼ 19). Data are shown as median and 25th
and 75th percentiles.
Table 1 | Baseline indices (mean7s.e.m., or median and
interquartile range) in patients with chronic renal failure
Active group
(n=11)
Control group
(n=8)
Normal
range
Age (years) 44.778 45.175 —
Weight (kg) 67.576 67.474 —
Plasma BUN (mg/dl) 80 (59, 115) 92 (77, 114) 5–25
Plasma creatinine
(mg/dl)
10.0 (6.6, 15.3) 7.4 (4.9, 11.3) 0.5–1.5
Plasma BNP (pmol/l 13.5 (8.0, 49.7) 14.1 (5.5, 149.6) 3–12
Plasma NT-BNP (pmol/l) 54 (41, 678) 81 (27, 1500) 2–50
Plasma NT-CNP (pmol/l) 269 (212, 321)** 148 (93, 167) 13–29
Plasma adrenomedullin
(pmol/l)
9.5 (7.9, 18.7) 9.6 (7.6, 32.7) 4–28
**Po0.01 compared to the control group.
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Figure 2 | Plasma levels of creatinine and NT-CNP in 19 patients
with chronic renal failure.
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increasing minimally (by 4.9%) with a low-flux membrane.
MacGregor et al.11 reported a statistically significant though
minor rise in NT-BNP with haemodialysis. The effect of
peritoneal dialysis on circulating NT-BNP has not, to our
knowledge, been reported.
In the present study, we have confirmed earlier reports
that plasma levels of BNP and NT-BNP are elevated in
patients with chronic renal failure. In addition, we demon-
strate that peritoneal dialysis had no major effect on
circulating levels of either BNP or NT-BNP. We presume,
therefore, that the dialysis-induced fall in volume of
distribution for these peptides balanced any reduction in
their cardiac secretion (resulting from a probable decrease in
cardiac preload and afterload) and clearance by dialysis.
Our data do not allow us to comment on circulating levels
of the cardiac natriuretic peptides in patients receiving
different types of dialysis. In this regard, Nagatani et al.13
noted that plasma levels of BNP were significantly (61%)
lower in 32 patients on chronic ambulatory peritoneal
dialysis than in 63 patients receiving maintenance haemo-
dialysis, thereby raising the possibility that ventricular load
was lower and volume control was superior in the former
group of patients.
We were interested to document plasma levels of NT-CNP
and adrenomedullin in chronic renal failure and the effects of
peritoneal dialysis, as it seems likely that these peptides (or
CNP in the case of NT-CNP) are protective of cardiovascular
and renal structure and function.14–18 Such information,
therefore, may be of pathophysiological and therapeutic
interest. It has been shown previously that plasma levels of
immunoreactive CNP are elevated in patients with renal
impairment.19,20 We now show that circulating NT-CNP,
which may prove to be a superior index of CNP production
than CNP levels (which are extremely low or undetectable in
normal subjects9,15), are also greatly elevated in patients with
longstanding renal failure. Indeed, the levels were much
higher than reported earlier in healthy volunteers and in
patients with cardiac failure.9 One caveat here is that our
patients with chronic renal failure were considerably younger
than control subjects or patients with heart failure, although
this is unlikely to account for the sizeable differences in NT-
CNP levels between the groups since Wright et al.9 noted only
modest, and positive relationships between NT-CNP levels
and age in healthy volunteers and in patients with cardiac
failure. As in the study of Wright et al.9 in patients with heart
failure, we observed a significant, if modest, positive
association between plasma creatinine and NT-CNP. Whether
this represents heightened secretion of the peptide, a
reduction in its clearance from the circulation or a combi-
nation of both remains to be determined. Likewise, the
source of the CNP peptides in patients with renal impairment
is uncertain. Whereas the vascular endothelium is one
obvious possibility,14 increased chondrocyte secretion21,22 in
patients with renal osteodystrophy is another.
It is not known whether NT-CNP has biological effects, but
the demonstrated actions of CNP (such as inhibition of
cardiac myocyte hypertrophy,23 prevention of vascular re-
sponses to experimental injury24,25 and inhibition of atheros-
clerosis in animals26) might provide some protection against
the widespread cardiovascular damage that typifies and
complicates chronic renal failure.27
Whether NT-CNP levels will prove useful in the clinical
assessment of patients on maintenance dialysis remains to be
determined. One theoretical possibility in this regard is that it
might provide an index of pathology within the vasculature,
thereby complementing the BNPs, which may well find
clinical usage in reflecting cardiac impairment and prog-
nosis,4 and providing guidance to overall management in
patients receiving chronic dialysis.5
Adrenomedullin, a 52-amino-acid peptide derived largely
from vascular tissues, has numerous effects within the
kidneys and on the cardiovascular and renin–angiotensin
systems.28 These protean actions of adrenomedullin are
generally seen as protective against injury due to hyperten-
sion, cardiovascular trophic and toxic factors, and infec-
tion.28,29 The hormone circulates in higher than normal
concentrations in patients with renal impairment and is
altered variably by haemodialysis.11,30–34 We confirm here
that immunoreactive adrenomedullin levels are elevated
indeed in patients with chronic renal impairment. Also, we
show that circulating levels of adrenomedullin are not altered
significantly across peritoneal dialysis.
In summary, we have demonstrated that plasma levels of
BNP, NT-BNP, NT-CNP and adrenomedullin are elevated in
patients with chronic renal failure requiring regular perito-
neal dialysis. Levels of these peptides, which in the case of
NT-CNP correlated with indices of renal function, were not
altered by peritoneal dialysis.
Table 2 | Peptide hormone levels (median and interquartile range) before, during and after peritoneal dialysis (active group)
and between dialyses (control group)
Active group (n=11) Control group (n=8)
Baseline During dialysis After dialysis Baseline During dialysis After dialysis
Plasma BNP (pmol/l) 13.5 (8.0, 49.7) 11.3 (9.9, 52.1) 24.7 (7.6, 62.5) 14.1 (5.5, 149.6) 13.1 (6.3, 146.5) 13.7 (5.5, 139.9)
Plasma NT-BNP (pmol/l) 54 (41, 678) 63 (42, 652) 148 (41, 767) 81 (27, 1500) 87 (26, 1531) 79 (30, 1372)
Plasma NT-CNP (pmol/l) 269 (212, 321) 260 (177, 360) 286 (214, 369) 148 (93, 167) 135 (99, 216) 135 (99, 234)
Plasma adrenomedullin (pmol/l) 9.5 (7.9, 18.7) 13.7 (7.8, 15.1) 11.2 (9.3, 13.3) 9.6 (7.6, 32.7) 7.7 (6.7, 37.0) 8.1 (5.2, 28.8)
For the control group, the baseline, during dialysis and after dialysis samples were all drawn between regular peritoneal dialyses.
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MATERIALS AND METHODS
The study protocol was approved by the Ethics Committee of the
Faculty of Medicine and Health Sciences at the UAE University. We
studied 19 patients, 17 males, aged 28–72 years, with chronic renal
failure resulting from diabetes mellitus in 12 patients but of
uncertain aetiology in the other patients (presumed glomerulo-
nephritis and/or hypertension). All had been on long-term (at least
4 months) intermittent peritoneal dialysis and all patients had
residual renal function. A total of 13 were from the Indian
subcontinent, two were of African origin and four were from Arab
countries, but all were treated and studied in one of three hospitals
within the United Arab Emirates. No patient had clinical evidence of
heart failure at the time of study, although most had exhibited fluid
overload before the initiation of peritoneal dialysis.
In 11 of the 19 patients (active group), blood samples were
drawn from a forearm vein 15 min before and again immediately
before a session of regular peritoneal dialysis (baseline), after 2 and
4 h of dialysis, and finally 1 h after completion of dialysis. The
number of dialysis cycles in individuals varied between 5 and 30. We
did not collect peritoneal dialysate for peptide measurements. The
remaining eight patients (control group) had venous samples drawn
as above but in the absence of peritoneal dialysis. Blood was taken
into chilled tubes containing ethylenediaminetetraacetic acid and
centrifuged at þ 41C, and the plasma was stored at 801C. Plasma
samples were couriered on dry ice as a single batch to Christchurch,
New Zealand for peptide measurements by the staff who were
blinded as to the grouping of patients. Established radioimmuno-
assay methods were used to measure BNP,35 the NT-BNP,36 the NT-
CNP7 and adrenomedullin.37 The interassay coefficient of variation
was between 5.8% for NT-CNP at 15.9 pmol/l and 28.8% for
adrenomedullin at 3.8 pmol/l. The intra-assay coefficient of varia-
tion was between 3.7% for NT-BNP at 200 pmol/l and 14.5% for
adrenomedullin at 3.1 pmol/l. Plasma BUN and creatinine were
measured in a single batch using a Synchron CX9 ALX autoanalyser
(Beckman-Coulter).
Differences between indices at baseline in the active and
control groups were compared using the Mann–Whitney U-test
and relationships between indices were assessed using Spearman’s
correlation coefficient. For the purposes of assessing changes
across dialysis in the active group and for comparison over time
in the control group, results from the two predialysis data points
and the two intradialysis data points were each taken as a single
mean. Changes between the two groups were calculated and
compared also using the non-parametric Mann–Whitney U-test.
Unless otherwise stated, results are shown as median and
interquartile range.
NOTE ADDED IN PROOF
Since submission of this manuscript, a comprehensive review
of the natriuretic peptides in end-stage renal disease has been
published.38
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